{"text": "Canagliflozin 100 mg : Baseline to Week 104 .Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "21.360907"}
{"text": "Canagliflozin 300 mg : Baseline to Week 104 .Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "22.077473"}
{"text": "Canagliflozin 300 mg : Baseline to Week 26 .Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "23.05223"}
{"text": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .Canagliflozin 300 mg .", "label": "", "metadata": {}, "score": "28.70433"}
{"text": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .Canagliflozin 300 mg .", "label": "", "metadata": {}, "score": "28.70433"}
{"text": "Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .Canagliflozin 300 mg .", "label": "", "metadata": {}, "score": "28.70433"}
{"text": "Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "29.684513"}
{"text": "Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "29.684513"}
{"text": "Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "29.761715"}
{"text": "Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "29.761715"}
{"text": "Data are presented for Baseline to Week 26 .Canagliflozin 100 mg : Baseline to Week 26 .Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "31.695728"}
{"text": "The trials are being conducted to assess the safety and efficacy of canagliflozin dosed at 100 or 300 mg as monotherapy and in combination with oral antihyperglycemic agents and/or insulin .", "label": "", "metadata": {}, "score": "32.157852"}
{"text": "Drug : Canagliflozin .One 100 mg or 300 mg over - encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone .", "label": "", "metadata": {}, "score": "34.188305"}
{"text": "The data were presented at the 70th American Diabetes Association ( ADA ) Scientific Sessions .Canagliflozin is a member of a new class of antihyperglycemic therapies under development to treat type 2 diabetes .", "label": "", "metadata": {}, "score": "35.546604"}
{"text": "Thus , 500 mg dapagliflozin caused 58 g UGE/24 h. Similar observations have been reported with other SGLT2 inhibitors currently under clinical development ( 9 ) .", "label": "", "metadata": {}, "score": "35.56703"}
{"text": "If necessary , the dose can be increased to 300 mg once daily .If you take too much canagliflozin , call your doctor or local poison control center , or seek emergency medical attention right away .", "label": "", "metadata": {}, "score": "36.62117"}
{"text": "Canagliflozin , a novel inhibitor of sodium glucose co - transporter 2 , dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects .", "label": "", "metadata": {}, "score": "36.826534"}
{"text": "Two canagliflozin / metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2 .Experimental : Treatment Sequence BA .Drug : B ( canagliflozin / metformin IR FDC tablets / A ( canagliflozin and metformin IR individual tablets ) .", "label": "", "metadata": {}, "score": "39.05115"}
{"text": "Your doctor may do certain blood tests before you start canagliflozin and during treatment as needed .Your doctor may change your dose of canagliflozin based on the results of your blood tests .", "label": "", "metadata": {}, "score": "40.842903"}
{"text": "Urine concentrations of canagliflozin to evaluate protocol - specified pharmacokinetic parameters [ Time Frame : At protocol - specified time points after dosing on Day 1 through Day 3 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "41.614258"}
{"text": "Study results demonstrated that administration of INVOKAMET was equivalent to co - administration of corresponding doses of canagliflozin and metformin as individual tablets .INVOKAMET will be available in tablets containing canagliflozin 50 milligrams ( mg ) or 150 mg , and metformin 500 mg or 1000 mg .", "label": "", "metadata": {}, "score": "41.727406"}
{"text": "A non - dose - dependent increase in vulvovaginal candidal infections was seen in subjects receiving canagliflozin .The incidence of hypoglycemic events was low and similar in the canagliflozin and placebo treatment groups .", "label": "", "metadata": {}, "score": "42.06831"}
{"text": "It is taken by mouth , usually once daily before breakfast .Common side effects include yeast infections and urinary tract infections .This is not a complete list of canagliflozin drug interactions .", "label": "", "metadata": {}, "score": "42.19864"}
{"text": "The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and have inadequate glycemic ( blood sugar ) control .", "label": "", "metadata": {}, "score": "42.53314"}
{"text": "The study was not powered to compare efficacy between canagliflozin and sitagliptin .In general , adverse events were mild to moderate and the overall incidence was balanced across all arms of the study .", "label": "", "metadata": {}, "score": "42.88589"}
{"text": "Official Title : .An Open - Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin ( JNJ-28431754 ) and Metformin Following Once - Daily Administration of 2 Canagliflozin / Metformin XR ( 150/1,000-mg )", "label": "", "metadata": {}, "score": "44.24434"}
{"text": "Canagliflozin is a drug that is being tested to see if it may be useful in treating patients diagnosed with type 2 diabetes mellitus ( T2DM ) .", "label": "", "metadata": {}, "score": "44.55758"}
{"text": "Official Title : .An Open - Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of 300 mg JNJ-28431754 ( Canagliflozin ) in Subjects With Various Degrees of Impaired Hepatic Function Compared With Subjects With Normal Hepatic Function .", "label": "", "metadata": {}, "score": "44.803055"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01186588 The purpose of this study is to evaluate the multiple dose pharmacokinetics of 2 Canagliflozin / extended release Metformin ( CANA / MET XR ) fixed dose combination tablets ( 150 mg/1,000 mg each ) following once - daily oral dosing in healthy participants .", "label": "", "metadata": {}, "score": "45.051033"}
{"text": "In subjects randomized to placebo , A1C decreased by 0.2 percent .Body weight , a key secondary endpoint , decreased from baseline in patients receiving canagliflozin by 2.3 to 3.4 percent compared to a 1.1 percent weight loss in subjects in the placebo arm .", "label": "", "metadata": {}, "score": "45.647804"}
{"text": "It is not known if canagliflozin will harm your unborn baby .If you are pregnant , talk with your doctor about the best way to control your blood sugar while you are pregnant .", "label": "", "metadata": {}, "score": "45.665302"}
{"text": "Each patient will receive 2 tablets of CANA / MET XR combination of total dose 300/2000 mg .Drug : CANA / MET XR FDC .", "label": "", "metadata": {}, "score": "45.906555"}
{"text": "Dapagliflozin is approved in Europe , and canagliflozin recently was approved in the U.S.This class of drugs lowers the plasma glucose concentration by inhibiting SGLT2 , leading to glucosuria .", "label": "", "metadata": {}, "score": "46.244938"}
{"text": "Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone .Drug : Canagliflozin .One 100 mg or 300 mg over - encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone .", "label": "", "metadata": {}, "score": "46.260258"}
{"text": "A Single - Dose , Open - Label , Randomized , 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release ( IR ) ( 150 mg/850 mg )", "label": "", "metadata": {}, "score": "46.463997"}
{"text": "Urine concentrations of canagliflozin metabolites ( M5 and M7 ) to evaluate protocol - specified pharmacokinetic parameters [ Time Frame : At protocol - specified time points after dosing on Day 1 through Day 3 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "47.026535"}
{"text": "About Canagliflozin .J&JPRD and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation .Ortho - McNeil - Janssen Pharmaceuticals , Inc. has marketing rights in North America , South America , Europe , Middle East , Africa , Australia , New Zealand and parts of Asia .", "label": "", "metadata": {}, "score": "47.205208"}
{"text": "Drug : Canagliflozin 100 mg Drug : Canagliflozin 300 mg Drug : Antihyperglycemic agent(s )Drug : Placebo .Key information relevant to the recruitment process for the overall study , such as dates of the recruitment period and locations .", "label": "", "metadata": {}, "score": "47.256157"}
{"text": "It is not known if canagliflozin passes into your breast milk .Talk with your doctor about the best way to feed your baby if you are taking canagliflozin .", "label": "", "metadata": {}, "score": "47.369156"}
{"text": "It belongs to a group of drugs called sodium - glucose co - transporter 2 ( SGLT2 ) inhibitors .Canagliflozin lowers blood sugar by causing the kidneys to get rid of more glucose in the urine .", "label": "", "metadata": {}, "score": "47.47694"}
{"text": "The purpose of the study is to determine the concentration of canagliflozin in blood and urine samples after the administration of canagliflozin to study participants with mild or moderate hepatic ( liver ) impairment compared with study participants with normal hepatic function .", "label": "", "metadata": {}, "score": "47.493008"}
{"text": "Canagliflozin can cause some people to have dehydration ( the loss of body water and salt ) .Dehydration may cause you to feel dizzy , faint , lightheaded , or weak , especially when you stand up ( orthostatic hypotension ) .", "label": "", "metadata": {}, "score": "47.503822"}
{"text": "Diabetes Care 2010 ; 33 : 2217 - 2224 pmid : 20566676 .Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion : results of a randomized , placebo - controlled study .", "label": "", "metadata": {}, "score": "47.68988"}
{"text": "Before you take canagliflozin , tell your doctor if you : . have kidney problems .have liver problems . are on a low sodium ( salt ) diet .", "label": "", "metadata": {}, "score": "47.715828"}
{"text": "Detailed Description : .This is an open - label ( physicians and participants know the identity of the assigned treatment ) , multiple - dose , single - center , pharmacokinetic study of a fixed dose combination ( FDC ) of 150 mg/1,000 mg Canagliflozin / extended release Metformin ( CANA / MET XR ) tablets .", "label": "", "metadata": {}, "score": "49.465866"}
{"text": "A recent 24-week clinical trial has reported an 11 and 20 % increase in fasting and postprandial GLP-1 levels in newly diagnosed T2DM individuals receiving a mean of 268 mg acarbose / day ( 22 ) .", "label": "", "metadata": {}, "score": "50.53881"}
{"text": "Take canagliflozin by mouth 1 time each day exactly as your doctor tells you to take it .Your doctor will tell you how much canagliflozin to take and when to take it .", "label": "", "metadata": {}, "score": "50.911404"}
{"text": "After study drug administration , study participants will be provided with standardized meals ( breakfast , lunch , and dinner ) .Blood and urine samples for analyses of canagliflozin and metabolites ( M7 and M5 ) will be collected from study participants at specified time points up to 120 hours ( blood ) and 48 hours ( urine ) after study drug administration .", "label": "", "metadata": {}, "score": "51.423775"}
{"text": "The efficacy of SGLT2 inhibitors to reduce the HbA 1c and promote weight loss is highly dependent upon the amount of glucosuria produced by these agents .", "label": "", "metadata": {}, "score": "51.789253"}
{"text": "Talk to your doctor if you have questions about a missed dose .If you take too much canagliflozin , call your doctor or go to the nearest hospital emergency room right away .", "label": "", "metadata": {}, "score": "52.533012"}
{"text": "The total duration of the study will be about 42 days for each participant .During the Open - Label Treatment Phase , approximately 12 healthy adult participants will receive a single oral dose of 2 CANA / MET XR tablets once daily for 7 days after a provided dinner .", "label": "", "metadata": {}, "score": "52.582985"}
{"text": "One 100 mg over - encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone .Drug : Metformin .", "label": "", "metadata": {}, "score": "53.022522"}
{"text": "Tell your doctor right away if you have any of these conditions and follow your doctor 's instructions .Stay on your prescribed diet and exercise program while taking canagliflozin .", "label": "", "metadata": {}, "score": "53.431774"}
{"text": "These results indicate that , in the presence of SGLT2 , the contribution of SGLT1 to renal glucose reabsorption is minimal .Conversely , under conditions of SGLT2 inhibition , elimination of renal glucose reabsorption by SGLT1 profoundly enhances UGE .", "label": "", "metadata": {}, "score": "53.532524"}
{"text": "However , the combination of SGLT1 plus SGLT2 inhibition would be expected to produce a robust glucosuria and greater decrease in the plasma glucose concentration .", "label": "", "metadata": {}, "score": "54.627434"}
{"text": "It is best to take canagliflozin before the first meal of the day .Your doctor may tell you to take canagliflozin along with other diabetes medicines .", "label": "", "metadata": {}, "score": "54.742878"}
{"text": "Janssen Pharmaceuticals announced that the U.S. Food and Drug Administration ( FDA ) has approved INVOKAMET , a fixed - dose therapy combining canagliflozin and metformin hydrochloride in a single tablet , for the treatment of adults with type 2 diabetes .", "label": "", "metadata": {}, "score": "54.886242"}
{"text": "Inhibiting SGLT2 is believed to reduce blood glucose levels by increasing the amount of glucose excreted in the urine , which may also lead to a loss of calories .", "label": "", "metadata": {}, "score": "55.235767"}
{"text": "We recognize that complete inhibition of SGLT1 will produce severe gastrointestinal side effects , which may preclude the clinical utility of a potent combined SGLT1/SGLT2 inhibitor , e.g. , phlorizin .", "label": "", "metadata": {}, "score": "55.250366"}
{"text": "With respect to this , studies with canagliflozin ( 19 ) and LX4211 ( 20 ) , which partially inhibit gut SGLT1 , were not associated with gastrointestinal side effects .", "label": "", "metadata": {}, "score": "55.35177"}
{"text": "If you have any symptoms of a serious allergic reaction , stop taking canagliflozin and call your doctor right away or go to the nearest hospital emergency room .", "label": "", "metadata": {}, "score": "55.376465"}
{"text": "LX4211 increases serum glucagon - like peptide 1 and peptide YY levels by reducing sodium / glucose cotransporter 1 ( SGLT1)-mediated absorption of intestinal glucose .", "label": "", "metadata": {}, "score": "55.471207"}
{"text": "In two studies comparing INVOKANA@ plus metformin to current standard treatments plus metformin - one studying sitagliptin and the other studying glimepiride - INVOKANA@ dosed at 300 mg provided greater reductions in A1C levels and body weight than either comparator .", "label": "", "metadata": {}, "score": "55.61297"}
{"text": "Therefore , we anticipate that the clinical efficacy of SGLT2 inhibitors will be greater in subjects with a high HbA 1c compared with those with low HbA 1c .", "label": "", "metadata": {}, "score": "55.72927"}
{"text": "However , the maximal amount of glucose excreted in the urine is far lower than that taken up by SGLT2 in normal glucose tolerant ( NGT ) individuals and does not exceed 35 - 40 % of the filtered glucose load .", "label": "", "metadata": {}, "score": "56.773323"}
{"text": "Do not take canagliflozin if you : . are allergic to canagliflozin or any of the ingredients in canagliflozin .Symptoms of allergic reaction to canagliflozin may include : . rash . swelling of the face , lips , tongue , and throat that may cause difficulty in breathing or swallowing . have severe kidney problems or are on dialysis .", "label": "", "metadata": {}, "score": "57.188484"}
{"text": "The statistical analyses show the treatment differences ( ie , each canagliflozin group minus placebo ) in the LS mean percent change .Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone .", "label": "", "metadata": {}, "score": "57.199917"}
{"text": "Patients will participate in the study for approximately 59 to 78 weeks .During the study , if a patient 's fasting blood sugar remains high despite treatment with study drug , the patient will receive treatment with glimepiride ( rescue therapy ) in accordance with local prescribing information .", "label": "", "metadata": {}, "score": "57.37134"}
{"text": "The statistical analyses show the treatment differences ( ie , each canagliflozin group minus placebo ) in the LS mean change .Change in Homeostasis Model Assessment ( HOMA2-%B )", "label": "", "metadata": {}, "score": "57.398403"}
{"text": "Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats .Am J Physiol Endocrinol Metab 2013 ; 304 : E414 - E423 pmid : 23249697 .", "label": "", "metadata": {}, "score": "57.418716"}
{"text": "4 ) .This prediction is consistent with the relationship between the fractional excretion of glucose and the amount of glucose that is filtered ( which reflects the level of plasma glucose concentration ) in SGLT2 knockout mice .", "label": "", "metadata": {}, "score": "58.168404"}
{"text": "Glucosuria is produced only if the filtered glucose load exceeds 350 mg / min , as may occur in individuals with poorly controlled diabetes .Under these conditions , the T max is exceeded and all of the filtered glucose in excess of the T max is excreted in the urine .", "label": "", "metadata": {}, "score": "58.71178"}
{"text": "Based upon our hypothesis , the fraction of filtered glucose excreted by SGLT2 inhibitors will increase with the increase in the plasma glucose concentration ( Fig .", "label": "", "metadata": {}, "score": "58.763496"}
{"text": "No text entered .Reporting Groups .Description .Placebo .Each participant received matching placebo once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .", "label": "", "metadata": {}, "score": "59.14645"}
{"text": "The primary outcome measure in the study is the effect of canagliflozin relative to placebo on hemoglobin A1c ( HbA1c ) after 26 weeks of treatment .", "label": "", "metadata": {}, "score": "59.561172"}
{"text": "Thus , under physiologic conditions SGLT1 operates at only 10 - 15 % of its maximal transport capacity ( Fig . 1 ) .How do SGLT2 inhibitors affect renal glucose reabsorption ?", "label": "", "metadata": {}, "score": "59.66416"}
{"text": "Thus , the combination of dipeptidyl peptidase-4 inhibitor with such a dual SGLT1/SGLT2 inhibitor will also activate the incretin axis and would have a robust effect in lowering the plasma glucose concentration and body weight ( 23 ) .", "label": "", "metadata": {}, "score": "60.01087"}
{"text": "The Phase 3 studies evaluated INVOKANA in combination with metformin compared to metformin alone or to metformin plus another diabetes therapy .The studies were part of the comprehensive global Phase 3 program for INVOKANA@ that enrolled 10,285 patients , one of the largest clinical programs in type 2 diabetes submitted to health authorities to date .", "label": "", "metadata": {}, "score": "60.109997"}
{"text": "Description .Placebo .Each participant received matching placebo once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .", "label": "", "metadata": {}, "score": "60.385193"}
{"text": "Drug : B ( canagliflozin / metformin IR FDC tablets / A ( canagliflozin and metformin IR individual tablets ) .Allocation : Randomized Endpoint Classification : Bio - equivalence Study Intervention Model : Crossover Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "60.697357"}
{"text": "The maximal SGLT1 transport capacity was estimated at 120 g / day ( see text for details ) .GFL , glucose filtration load .Conversely , under hypoglycemic conditions that decrease the filter glucose load below the SGLT1 maximal transport capacity , SGLT2 inhibition will produce no glucosuria .", "label": "", "metadata": {}, "score": "60.700146"}
{"text": "Since the mechanism of action of the SGLT2 inhibitors is independent of insulin action and insulin secretion , they lower the plasma glucose concentration without increasing the risk of hypoglycemia .", "label": "", "metadata": {}, "score": "60.740765"}
{"text": "Patients will take single - blind placebo capsules for 2 weeks before randomization .After randomization , patients will take double - blind canagliflozin ( 100 mg or 300 mg ) for 52 weeks OR placebo for 26 weeks switched to double - blind sitagliptin 100 mg for 26 weeks .", "label": "", "metadata": {}, "score": "60.812485"}
{"text": "As a result , the amount of glucose excreted in the urine is significantly less than that taken up by the SGLT2 transporter under physiologic conditions .", "label": "", "metadata": {}, "score": "61.05922"}
{"text": "Because of the potential gastrointestinal side effects associated with SGLT1 inhibition , pharmaceutical companies have selected agents with greater selectivity for SGLT2 over SGLT1 for clinical development .", "label": "", "metadata": {}, "score": "61.139774"}
{"text": "Laboratory test results [ Time Frame : From Screening ( up to 23 days prior to dosing ) to 7 to 10 days after Day 6 or at the time of early withdrawal from the study . ]", "label": "", "metadata": {}, "score": "61.139885"}
{"text": "In this Perspective , we suggest an explanation for this paradox , discuss some of the clinical implications of this explanation , and suggest mechanisms to improve the clinical efficacy of SGLT2 inhibitors .", "label": "", "metadata": {}, "score": "61.33783"}
{"text": "Drug : Pioglitazone .The patient 's stable dose of pioglitazone background therapy should be continued throughout the study .Experimental : Canagliflozin 100 mg .", "label": "", "metadata": {}, "score": "61.7127"}
{"text": "( 1 ) Baseline A1C levels for patients randomized to canagliflozin ranged from 7.6 to 8.0 .Baseline A1C in the placebo arm was 7.7 .", "label": "", "metadata": {}, "score": "61.892876"}
{"text": "The table below shows the least - squares ( LS ) mean change in HbA1c from Baseline to Week 26 for each treatment group .The statistical analyses show the treatment differences ( ie , each canagliflozin group minus placebo ) in the LS mean change .", "label": "", "metadata": {}, "score": "62.023624"}
{"text": "If one assumes that inhibition of SGLT2 with a specific SGLT2 inhibitor completely blocks the transporter and produces maximal glucosuria , one can derive a reliable estimate of maximal SGLT1 glucose transport capacity .", "label": "", "metadata": {}, "score": "62.17882"}
{"text": "INVOKAMET is the first fixed - dose combination of an SGLT2 inhibitor with metformin approved in the United States .\" Canagliflozin works with the kidney to promote the loss of glucose in the urine , whereas metformin decreases the production of glucose in the liver and improves the body 's response to insulin . \" INVOKAMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled by treatment that includes either canagliflozin or metformin , or who are already being treated with both canagliflozin and metformin as separate medications .", "label": "", "metadata": {}, "score": "62.68192"}
{"text": "The table below shows the least - squares ( LS ) mean change in HbA1c from baseline to Week 18 for each treatment group .The statistical analyses show the treatment differences ( ie , each canagliflozin group minus placebo ) in the LS mean change .", "label": "", "metadata": {}, "score": "62.694588"}
{"text": "Drug : Placebo .One matching placebo capsule orally ( by mouth ) once daily for 26 weeks with stable doses of metformin and pioglitazone .", "label": "", "metadata": {}, "score": "62.993465"}
{"text": "Of note , the SGLT1 knockout mouse provides an opportunity to definitively test the present hypothesis by comparing the amount of glucosuria produced with a SGLT2 inhibitor in SGLT1 knockout mice versus that in wild - type animals .", "label": "", "metadata": {}, "score": "63.164955"}
{"text": "It is simply because they are specific SGLT2 inhibitors .Under physiologic conditions , SGLT1 operates at submaximal transport capacity .Complete inhibition of SGLT2 forces SGLT1 to reabsorb glucose in full capacity , and therefore , only the fraction of filtered glucose that escapes SGLT1 will be excreted in the urine .", "label": "", "metadata": {}, "score": "63.537914"}
{"text": "INVOKANA@ can increase the risk of hypoglycemia when combined with insulin or a medication that increases insulin levels ( e.g. , a sulfonylurea ) .Therefore , a lower dose of insulin or insulin - raising medication may be required to minimize the risk of hypoglycemia when used in combination with INVOKAMET .", "label": "", "metadata": {}, "score": "64.4891"}
{"text": "Table includes only participants with both baseline and post baseline values .Reporting Groups .Description .Placebo .Each participant received matching placebo once daily for 18 weeks with protocol - specified doses of metformin alone or metformin plus sulphonylurea .", "label": "", "metadata": {}, "score": "64.67946"}
{"text": "Therefore , additional antidiabetes agents that are effective in lowering the plasma glucose concentration without weight gain and hypoglycemia are required for the treatment of T2DM individuals .", "label": "", "metadata": {}, "score": "64.73998"}
{"text": "We suggest that SGLT2 inhibitors force SGLT1 to reabsorb glucose at its maximum capacity .Therefore , we would anticipate that , under conditions of complete SGLT2 inhibition , inhibition of SGLT1 will produce marked glucosuria .", "label": "", "metadata": {}, "score": "65.42685"}
{"text": "Reporting Groups .Description .Placebo .Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "66.499954"}
{"text": "Adverse events [ Time Frame : Up to approxmately 23 days ] [ Designated as safety issue : No ] .The number and type of adverse events will be reported from Day 1 of treatment period 1 through 7 - 10 days after treatment period 2 including the 10 - 15 washout period between treatment periods ( total time is approximately 23 days ) .", "label": "", "metadata": {}, "score": "66.59953"}
{"text": "R.A.D. and L.N. contributed to revising and reviewing the manuscript . . .Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "66.708496"}
{"text": "Placebo : Baseline to Week 104 .Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "67.19589"}
{"text": "Patients randomized to these arms had observed mean A1C reductions from baseline(1 ) of 0.8 , 0.8 , 0.7 , 0.9 and 0.9 percent , respectively .", "label": "", "metadata": {}, "score": "67.24654"}
{"text": "[ Designated as safety issue : No ] .Vital signs measurements and results from electrocardiograms [ Time Frame : From Screening ( up to 23 days prior to dosing ) to 7 to 10 days after Day 6 or at the time of early withdrawal from the study . ]", "label": "", "metadata": {}, "score": "68.023026"}
{"text": "Participant flow is presented for Baseline to Week 104 ( Overall Study ) .Reporting Groups .Description .Placebo .Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic ( AHA ) regimen at the time of study entry .", "label": "", "metadata": {}, "score": "68.141914"}
{"text": "The table below shows the least - squares ( LS ) mean change in SBP from Baseline to Week 26 for each treatment group .The statistical analyses show the treatment differences ( ie , each canagliflozin group minus placebo ) in the LS mean change .", "label": "", "metadata": {}, "score": "68.17525"}
{"text": "low blood sugar ( hypoglycemia ) .If you take canagliflozin with another medicine that can cause low blood sugar , such as a sulfonylurea or insulin , your risk of getting low blood sugar is higher .", "label": "", "metadata": {}, "score": "68.768814"}
{"text": "Physical examination findings [ Time Frame : From Screening ( up to 23 days prior to dosing ) to 7 to 10 days after Day 6 or at the time of early withdrawal from the study . ]", "label": "", "metadata": {}, "score": "68.78518"}
{"text": "Vaginal yeast infection .Women who take canagliflozin may get vaginal yeast infections .Symptoms of a vaginal yeast infection include : . vaginal odor .", "label": "", "metadata": {}, "score": "69.03691"}
{"text": "Study participants will be required to stay overnight at the study center for 5 nights to receive study drug and have study procedures and safety assessments performed .", "label": "", "metadata": {}, "score": "70.24538"}
{"text": "However , none are completely satisfactory .Physiologic considerations .It should be emphasized that this T max represents the sum of maximal transport capacity of SGLT1 plus SGLT2 .", "label": "", "metadata": {}, "score": "70.37159"}
{"text": "Change in Fasting Plasma Glucose ( FPG )From Baseline to Week 26 [ Time Frame : Day 1 ( Baseline ) and Week 26 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "70.70239"}
{"text": "Primary Purpose : Treatment .Official Title : .A Randomized , Double - Blind , Placebo - Controlled , 3-Arm , Parallel - Group , Multicenter Study to Evaluate the Efficacy , Safety , and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy .", "label": "", "metadata": {}, "score": "71.11685"}
{"text": "Study participants are to remain standing or sitting for the first 4 hours after dosing .At 2 hours after dosing ( but not earlier ) all study participants must drink 1 glass of water ; drinking of water is allowed from then onwards .", "label": "", "metadata": {}, "score": "71.24272"}
{"text": "In total , 678 participants were randomly allocated to the 3 treatment arms , 676 received at least 1 dose of study drug and were included in the modified intent - to - treat ( mITT ) analysis set and the safety analysis set .", "label": "", "metadata": {}, "score": "71.41643"}
{"text": "In the two studies , the overall incidence of adverse events was similar with INVOKANA@ and the comparators .Results from the Phase 3 studies showed that the most common adverse events with INVOKANA@ are female genital mycotic ( fungal ) infections , urinary tract infections and increased urination .", "label": "", "metadata": {}, "score": "72.44858"}
{"text": "No well - controlled studies have been done in humans .Therefore , this medication may be used if the potential benefits to the mother outweigh the potential risks to the unborn child .", "label": "", "metadata": {}, "score": "72.766304"}
{"text": "Adverse event data was collected for the duration of the study ( 104 weeks ) .Additional Description .The total number of adverse events listed in the \" Other ( non - Serious )", "label": "", "metadata": {}, "score": "73.01214"}
{"text": "Measured Values .Placebo .Change in Glycosylated Hemoglobin ( HbA1c )From Baseline to Week 18 [ units : Percent ] Least Squares Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "73.14249"}
{"text": "The prescribing information for INVOKAMET also contains a boxed warning for lactic acidosis , a rare , but serious complication that can occur due to metformin accumulation .", "label": "", "metadata": {}, "score": "73.32008"}
{"text": "Is there really a paradox ?Under conditions of complete SGLT2 inhibitions , SGLT1 remains the sole mechanism of renal glucose reabsorption .Therefore , the amount of glucose excreted in the urine after maximal SGLT2 inhibition will be highly dependent upon the maximal SGLT1 glucose transport capacity and will equal the glucose filtration load minus the SGLT1 maximal glucose transport capacity .", "label": "", "metadata": {}, "score": "74.028275"}
{"text": "vaginal itching .Yeast infection of the penis ( balanitis or balanoposthitis ) .Men who take canagliflozin may get a yeast infection of the skin around the penis .", "label": "", "metadata": {}, "score": "74.23337"}
{"text": "Maximal SGLT1 transport capacity in humans .T max represents the maximal glucose transport capacity of both SGLT1 and SGLT2 .Thus , under conditions in which the SGLT2 transporter is completely inhibited , the renal T max represents the maximal SGLT1 glucose transport capacity ( Fig . 2 ) .", "label": "", "metadata": {}, "score": "74.27642"}
{"text": "The table below shows the least - squares ( LS ) mean percent change in triglycerides from Baseline to Week 26 for each treatment group .", "label": "", "metadata": {}, "score": "74.49095"}
{"text": "Immunohistochemical studies documented the absence of SGLT2 in the distal part of the proximal tubule .Thus , it is likely that the transport capacity of the distal part of the proximal tubule represents the transport capacity of SGLT1 .", "label": "", "metadata": {}, "score": "74.68181"}
{"text": "Percent Change in Body Weight From Baseline to Week 26 [ Time Frame : Day 1 ( Baseline ) and Week 26 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "74.901215"}
{"text": "Inhibitors of sodium - glucose cotransporter 2 ( SGLT2 ) are a novel class of antidiabetes drugs , and members of this class are under various stages of clinical development for the management of type 2 diabetes mellitus ( T2DM ) .", "label": "", "metadata": {}, "score": "75.23625"}
{"text": "The most common adverse reactions due to initiation of metformin , as noted in the prescribing information for that medication , are diarrhea , nausea / vomiting , flatulence , asthenia , indigestion , abdominal discomfort , and headache .", "label": "", "metadata": {}, "score": "75.570984"}
{"text": "The statistical analyses show the treatment differences ( ie , each canagliflozin group minus placebo ) in the LS mean percent change .Change in Systolic Blood Pressure ( SBP )", "label": "", "metadata": {}, "score": "75.71614"}
{"text": "Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .716 patients were randomly allocated to the 3 treatment arms .", "label": "", "metadata": {}, "score": "75.84375"}
{"text": "Change in Region Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual - energy X - ray Absorptiometry ( DXA ) Analysis for Body Composition [ Time Frame : Day 1 ( Baseline ) and Week 26 ] .", "label": "", "metadata": {}, "score": "76.018555"}
{"text": "The sponsor can not require changes to the communication and can not extend the embargo .The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days .", "label": "", "metadata": {}, "score": "76.35511"}
{"text": "In study participants with mild or moderate hepatic impairment , concomitant therapy to treat underlying disease states or medical conditions related to hepatic insufficiency are allowed .", "label": "", "metadata": {}, "score": "76.90102"}
{"text": "These are promising data that need to be confirmed in long - term trials , and I am looking forward to reviewing the results from those ongoing studies .", "label": "", "metadata": {}, "score": "77.053535"}
{"text": "It is also the second most common branded therapy prescribed by primary care physicians when adding or switching therapies in patients .Since its launch , more than one million prescriptions have been written for INVOKANA .", "label": "", "metadata": {}, "score": "77.26521"}
{"text": "Detailed Description : .Healthy volunteers participating in the study will be randomly ( by chance ) assigned to receive Treatment A followed by Treatment B or Treatment B followed by Treatment A with a period of approximately 15 days between treatments .", "label": "", "metadata": {}, "score": "77.346825"}
{"text": "Because many medications can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this medication , a choice should be made whether to stop nursing or stop the use of this medication .", "label": "", "metadata": {}, "score": "77.49783"}
{"text": "Study participants will be monitored for safety during the study by evaluating adverse events reported and results from clinical laboratory tests , 12-lead electrocardiograms ( ECGs ) , vital sign measurements , and physical examinations .", "label": "", "metadata": {}, "score": "77.82068"}
{"text": "Study participants with normal hepatic function must have blood pressure at screening and before study drug administration between 90 and 160 mmHg systolic , inclusive , and 55 and 100 mmHg diastolic , inclusive .", "label": "", "metadata": {}, "score": "79.21875"}
{"text": "If you miss a dose , take it as soon as you remember .If it is almost time for your next dose , skip the missed dose and take the medicine at the next regularly scheduled time .", "label": "", "metadata": {}, "score": "79.400406"}
{"text": "Percent Change in High - density Lipoprotein Cholesterol ( HDL - C )From Baseline to Week 26 [ Time Frame : Day 1 ( Baseline ) and Week 26 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "79.47351"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Analysis used overall mITT analysis set ( all randomized patients who received at least 1 dose of double - blind study drug ) .", "label": "", "metadata": {}, "score": "79.70914"}
{"text": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days .", "label": "", "metadata": {}, "score": "81.64622"}
{"text": "R.A.D. receives grant support from Takeda , Amylin , and Bristol - Myers Squibb .No other potential conflicts of interest relevant to this article were reported .", "label": "", "metadata": {}, "score": "81.70902"}
{"text": "In the following discussion , we will make several predictions based upon the hypothesis presented above , and we will contrast these predictions with published findings in order to test the validity of this hypothesis .", "label": "", "metadata": {}, "score": "81.770065"}
{"text": "A further list and description of these risks , uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson 's Annual Report on Form 10-K for the fiscal year ended January 3 , 2010 .", "label": "", "metadata": {}, "score": "81.86846"}
{"text": "However , the reabsorption and excretion curves display a nonlinear transition as the T max for glucose is approached .This \" rounding \" of the curves is termed splay and has been explained by heterogeneity in the T max of individual nephrons or glomerulotubular imbalance ( 4 ) .", "label": "", "metadata": {}, "score": "82.050735"}
{"text": "Medications can interact with certain foods .In some cases , this may be harmful and your doctor may advise you to avoid certain foods .", "label": "", "metadata": {}, "score": "82.10835"}
{"text": "Study participants with mild or moderate hepatic impairment who have a positive test for drugs of abuse , have severe ascites or pleural effusion ( accumulation of fluid in the abdomen and lungs , respectively ) , have a score of 3 or 4 for hepatic encephalopathy .", "label": "", "metadata": {}, "score": "82.216995"}
{"text": "It was conducted between 30 June 2011 and 21 December 2012 and recruited patients from 36 sites .Pre - Assignment Details .Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .", "label": "", "metadata": {}, "score": "82.46328"}
{"text": "All Rights Reserved .The purpose of this study is to evaluate the bioequivalence of fixed dose combination ( FDC ) tablets of canagliflozin and metformin immediate release ( IR ) in comparison with the individual components of canagliflozin and metformin IR .", "label": "", "metadata": {}, "score": "82.49642"}
{"text": "take medicines to lower your blood pressure , including diuretics ( water pill ) .are on low sodium ( salt ) diet . have kidney problems .", "label": "", "metadata": {}, "score": "82.91654"}
{"text": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days .", "label": "", "metadata": {}, "score": "83.05443"}
{"text": "The group allocation is based on the Child - Pugh score , an assessment of 5 clinical measures that is used to characterize the degree of hepatic impairment .", "label": "", "metadata": {}, "score": "83.209595"}
{"text": "All of the filtered glucose is reabsorbed by the kidney in the proximal tubule and returned to the circulation ( Fig . 1 ) by an SGLT mechanism ( 7 ) .", "label": "", "metadata": {}, "score": "83.3141"}
{"text": "Your doctor may suggest you use an over - the - counter antifungal medicine .Talk to your doctor right away if you use an over - the - counter antifungal medication and your symptoms do not go away . kidney problems .", "label": "", "metadata": {}, "score": "84.08827"}
{"text": "MEDDRA 14.0 used for Week 26 results/ MEDDRA 16.0 used for Week 104 results .Reporting Groups .Description .Placebo : Baseline to Week 26 .", "label": "", "metadata": {}, "score": "85.3759"}
{"text": "The SGLT2 transporter is expressed exclusively in the proximal tubule of the kidney , while SGLT1 primarily is expressed in the kidney and the gut , where it is responsible for the majority of glucose and galactose absorption in the gut .", "label": "", "metadata": {}, "score": "85.48804"}
{"text": "Janssen Pharmaceuticals , Inc. and its affiliates have marketing rights in North America , South America , Europe , the Middle East , Africa , Australia , New Zealand and parts of Asia .", "label": "", "metadata": {}, "score": "86.42462"}
{"text": "Day 1 ( Baseline ) and Week 18 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "86.56024"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT02039245 Key information relevant to the recruitment process for the overall study , such as dates of the recruitment period and locations .", "label": "", "metadata": {}, "score": "90.19458"}
{"text": "\" We are encouraged by these results and by the initiation of our Phase 3 program , which includes a large , prospective study assessing cardiovascular outcomes , \" said Martin Fitchet , M.D. , Global Therapeutic Area Head , Cardiovascular & Metabolism , J&JPRD .", "label": "", "metadata": {}, "score": "90.709595"}
{"text": "The patient 's stable dose of metformin background therapy should be continued throughout the study .Drug : Pioglitazone .The patient 's stable dose of pioglitazone background therapy should be continued throughout the study .", "label": "", "metadata": {}, "score": "91.32099"}
{"text": "The patient 's stable dose of metformin background therapy should be continued throughout the study .Drug : Pioglitazone .The patient 's stable dose of pioglitazone background therapy should be continued throughout the study .", "label": "", "metadata": {}, "score": "91.32099"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "91.38763"}
{"text": "Signs and symptoms of low blood sugar may include : . headache .drowsiness .weakness . dizziness . confusion . irritability . hunger .fast heart - beat .", "label": "", "metadata": {}, "score": "91.38959"}
{"text": "The study began on 07 June 2010 and ended on 23 May 2013 .Patients were recruited from 90 study centers located in 17 countries worldwide .", "label": "", "metadata": {}, "score": "91.99946"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01106690 .Diabetes Mellitus Diabetes Mellitus , Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Metformin Pioglitazone Sitagliptin Dipeptidyl - Peptidase IV Inhibitors .", "label": "", "metadata": {}, "score": "92.06711"}
{"text": "ACKNOWLEDGMENTS .R.A.D. is a member of the Advisory Board of Takeda , Bristol - Myers Squibb , Janssen , Boehringer Ingelheim , Novo Nordisk , Lexicon , and Amylin .", "label": "", "metadata": {}, "score": "92.62219"}
{"text": "Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed .Restriction Description : A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation .", "label": "", "metadata": {}, "score": "93.59662"}
{"text": "J&JPRD is focusing its drug discovery and drug development efforts to address unmet medical needs worldwide in a variety of therapeutic areas including cardiovascular and metabolic diseases , oncology , immunology , central nervous system disorders and virology .", "label": "", "metadata": {}, "score": "93.92352"}
{"text": "HOMA2-%B is a measure of beta cell function ( the cells in the pancreas that produce and store insulin ) .The table below shows the least - squares ( LS ) mean change in HOMA2-%B from Baseline to Week 26 for each treatment group .", "label": "", "metadata": {}, "score": "94.33621"}
{"text": "Exclusion Criteria : - History of or current medical illness , abnormal values for hematology or clinical chemistry laboratory tests , or abnormal physical examination , vital signs or 12-lead electrocardiogram ( ECG ) deemed to be clinically significant by the Investigator .", "label": "", "metadata": {}, "score": "94.37869"}
{"text": "Another important physiologic consideration that must be taken into account is the anatomical location of the two transporters .As stated earlier , SGLT2 is located in the proximal part of the proximal tubule ( S1 and S2 segments ) , while SGLT1 is located in the distal part ( S3 ) of the proximal tubule .", "label": "", "metadata": {}, "score": "95.55202"}
{"text": "Tell your doctor if you are pregnant or plan to become pregnant .The FDA categorizes medications based on safety for use during pregnancy .Five categories - A , B , C , D , and X , are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy .", "label": "", "metadata": {}, "score": "99.59494"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "99.64566"}
{"text": "Johnson & Johnson Pharmaceutical Research & Development , L.L.C. ( J&JPRD ) is a subsidiary of Johnson & Johnson , the world 's most broadly based producer of health care products .", "label": "", "metadata": {}, "score": "99.80493"}
{"text": "They are located in the luminal membrane of the proximal tubule cells and couple sodium and glucose transport from the glomerular filtrate into the tubular cell .", "label": "", "metadata": {}, "score": "99.95004"}
{"text": "This press release contains \" forward - looking statements \" as defined in the Private Securities Litigation Reform Act of 1995 .These statements are based on current expectations of future events .", "label": "", "metadata": {}, "score": "100.52742"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01518712 Allocation : Randomized ; Endpoint Classification : Safety / Efficacy Study ; Intervention Model : Parallel Assignment ; Masking : Double Blind ( Subject , Caregiver , Investigator ) ; Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "100.865906"}
{"text": "Other symptoms of yeast infection of the penis include : . redness , itching , or swelling of the penis . rash of the penis . foul smelling discharge from the penis . pain in the skin around penis .", "label": "", "metadata": {}, "score": "101.42676"}
{"text": "Includes whether analysis was per protocol , intention to treat , or another method .Also provides relevant details such as imputation technique , as appropriate .", "label": "", "metadata": {}, "score": "103.01427"}
{"text": "You should consult with a medical professional if you have any questions about your health .The use of any information on this site is solely at your own risk .", "label": "", "metadata": {}, "score": "103.28224"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "104.211"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "104.211"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "104.211"}
